Record: 1

03/27/2023

Company Report

Pages: 5

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Record: 2

11/29/2022

Daily Note

Pages: 3

XENLETA''s Safety and PK in CF Were Consistent With Historical Data; Company Future Remains Uncertain; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Record: 3

11/11/2022

Company Report

Pages: 7

3Q Recap; Nabriva to Focus on SIVEXTRO Only; Seeking Strategic Alternatives For Other Programs; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 4

08/12/2022

Company Report

Pages: 7

2Q Recap; SIVEXTRO Demand Hits New High Since Nabriva Took The Helm, But Cash Is Short; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 5

04/12/2022

Daily Note

Pages: 3

XENLETA Embarks on New Cystic Fibrosis Indication With First Patient Enrolled in Phase 1 Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Record: 6

03/30/2022

Company Report

Pages: 7

4Q Recap: Modest SIVEXTRO Growth to Continue in 2022; Still Awaiting Signs of XENLETA Traction; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 7

01/11/2022

Company Report

Pages: 6

4Q21 Preliminary Financial Results and 2022 Milestones Indicative of SIVEXTRO''s Continued Growth

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 8

10/11/2021

Industry Report

Pages: 8

IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Record: 9

10/06/2021

Daily Note

Pages: 4

Preclinical Data Reveals Potent Anti-Inflammatory Activity of XENLETA, Likely Expanding its Opportunity Set

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Record: 10

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NBRV

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Record: 11

09/10/2021

Daily Note

Pages: 3

Vizient Could Be Key Partner to Increase XENLETA Awareness in U.S. Hospital Setting; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 12

09/09/2021

Daily Note

Pages: 3

XENLETA Now Approved in Taiwan; NDA Filing Submission in China Expected in 2H21; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 13

08/09/2021

Company Report

Pages: 7

2Q21 Recap: SIVEXTRO Brings Much Needed Cash, But We Now Look for Steady Growth; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 14

08/02/2021

Company Report

Pages: 2

Termination of Sell Side Coverage

Provider: G.RESEARCH, LLC

Analyst: Research Department

Price: 10.00

Record: 15

06/07/2021

Company Report

Pages: 2

Cash Runway Extended Through Q1 2022

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 16

06/03/2021

Company Report

Pages: 4

Loan Amendment and ATM Use Extend Cash Runway; Maintain Neutral While We Await Signs of SIVEXTRO Traction

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Record: 17

05/27/2021

Company Report

Pages: 2

New Data, New Partner in China

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 18

05/26/2021

Company Report

Pages: 8

Positive XENLETA Data to Enable Likely China Approval; Exclusive SIVEXTRO Sales Begins; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Record: 19

05/10/2021

Company Report

Pages: 2

Q1 Results-Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Record: 20

04/16/2021

Company Report

Pages: 2

Revenue Inflection for Sivextro in Q2

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00